Device Trial Radar · NCT02974816
Glooko mHealth Advantage Study
Last checked: Nov 20, 2026Latest source record: Jun 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
197
Actual
Start
May 15, 2017
Primary completion
Apr 17, 2020
Study completion Apr 17, 2020
Sponsor
- Lead sponsor
- GlookoNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 28, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko
Conditions
- Diabetes Mellitus, Type 2
Interventions
Glooko's mobile applicationDevice
Standard of care and Remote monitoring
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c from baselineTime frame: 24 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
John Muir Physician Network Clinical Research Center
Concord, California
Sutter Health
Elk Grove, California
Scripps Whittier Diabetes Institute
San Diego, California
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.